Search

Kirk E Ekena

from Raleigh, NC
Age ~57
Get Report
Also known as:
Kirk G Ekena
Related to:
Christina L Stubbs, 54Jennifer Coalwell, 51Paul A Vansickle, 49Eric J Kraft, 56Dianne June Vansickle, 88Joanne L Ekena, 53Matthew D Vansickle, 46Danielle R Freund, 48David G Vansickle, 88
Connected to:
Sumer D Ekena, 47Robyn G Ekenes, 37Christopher A Ekeocha, 64Onyinyechi M Ekeocha, 41David A Eker, 51Tanner S Ekeren, 34Sarah E Ekerholm, 41Bert V Ekeris, 68Bryan A Ekern, 107Rodney A Ekern, 71

Kirk Ekena Phones & Addresses

  • Raleigh, NC
  • Fitchburg, WI
  • Urbana, IL
  • 295 E 30Th Ave, Eugene, OR 97405 (608) 288-8498
  • Madison, WI
  • Elmwood, IL
  • 5711 Richardson Cir, Fitchburg, WI 53711 (608) 628-4430

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: Graduate or professional degree

Emails

k***[email protected]

Publications

Us Patents

Reversible Modification Of Amine-Containing Compounds

View page
US Patent:
7442764, Oct 28, 2008
Filed:
Dec 20, 2005
Appl. No.:
11/312319
Inventors:
David B. Rozema - Madison WI, US
Darren Wakefield - Madison WI, US
Jon A. Wolff - Madison WI, US
Kirk Ekena - Madison WI, US
James E. Hagstrom - Middleton WI, US
Assignee:
Mirns Bio Corporation - Madison WI
International Classification:
C07K 1/107
A61K 38/00
C07K 2/00
US Classification:
530345, 530300, 514 2
Abstract:
An process for the reversible modification of an amine-containing compound is described. Modification of the compound can be used to facilitate delivery of molecules to cells in vitro and in vivo or to alter interactions or activities the compounds. The described modifiers can also be utilized as cross-linkers.

Protein And Peptide Delivery To Mammalian Cells In Vitro

View page
US Patent:
7476401, Jan 13, 2009
Filed:
Oct 12, 2005
Appl. No.:
11/248993
Inventors:
Sean D. Monahan - Madison WI, US
Vladimir G. Budker - Middleton WI, US
Kirk Ekena - Middleton WI, US
Lisa Nader - Madison WI, US
Assignee:
Mirus Bio LLC - Madison WI
International Classification:
A61K 9/127
A61K 48/00
C12N 15/88
US Classification:
424450, 435455, 435458
Abstract:
Compositions and methods for delivery of proteins and peptides to mammalian cells in vitro are described. Specifically, polypeptide-surfactant complexes formed from noncovalent hydrophobation of polypeptides and reversible hydrophobic modification of polypeptides are described. The compositions can be used to delivery positively charged, negatively charged and charge neutral polypeptides to cells.

Reversible Attachment Of A Membrane Active Polymer To A Polynucleotide

View page
US Patent:
7816337, Oct 19, 2010
Filed:
Feb 17, 2004
Appl. No.:
10/780484
Inventors:
David B. Rozema - Madison WI, US
Darren Wakefield - Fitchburg WI, US
Jon A Wolff - Fitchburg WI, US
Kirk Ekena - Fitchburg WI, US
James E. Hagstrom - Fitchburg WI, US
Assignee:
Roche Madison Inc. - Madison WI
International Classification:
A61K 31/70
C12N 5/00
C12N 15/00
US Classification:
514 44R, 424450, 435325, 435375, 435455
Abstract:
Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.

Endosomolytic Polymers

View page
US Patent:
8211468, Jul 3, 2012
Filed:
Sep 19, 2006
Appl. No.:
11/533115
Inventors:
David B. Rozema - Middleton WI, US
Darren H. Wakefield - Fitchburg WI, US
Jon A. Wolff - Madison WI, US
James E. Hagstrom - Middleton WI, US
Kirk Ekena - Fitchburg WI, US
Assignee:
Arrowhead Madison Inc. - Madison WI
International Classification:
A61K 9/32
C07D 207/444
US Classification:
424486, 548548
Abstract:
We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.

Reversible Modification Of Membrane Interaction

View page
US Patent:
20030220264, Nov 27, 2003
Filed:
May 23, 2003
Appl. No.:
10/444662
Inventors:
David Rozema - Madison WI, US
Darren Wakefield - Madison WI, US
Jon Wolff - Madison WI, US
Kirk Ekena - Madison WI, US
James Hagstrom - Middleton WI, US
International Classification:
A61K038/16
C07K014/16
US Classification:
514/012000, 530/350000, 530/406000
Abstract:
An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.

Protein And Peptide Delivery To Mammalian Cells In Vitro

View page
US Patent:
20040151766, Aug 5, 2004
Filed:
Jan 29, 2004
Appl. No.:
10/767329
Inventors:
Sean Monahan - Madison WI, US
Vladimir Budker - Middleton WI, US
Kirk Ekena - Middleton WI, US
Lisa Nader - Madison WI, US
International Classification:
A61K009/127
US Classification:
424/450000
Abstract:
Compositions and methods for delivery of proteins and peptides to mammalian cells in vitro are described. Specifically, polypeptide-surfactant complexes formed from noncovalent hydrophobation of polypeptides and reversible hydrophobic modification of polypeptides are described. The compositions can be used to delivery positively charged, negatively charged and charge neutral polypeptides to cells.

Reversibly Masked Polymers

View page
US Patent:
20150273081, Oct 1, 2015
Filed:
Jan 12, 2015
Appl. No.:
14/594229
Inventors:
- Madison WI, US
Jon A Wolff - Madison WI, US
James E Hagstrom - Middleton WI, US
Kirk Ekena - Fitchburg WI, US
International Classification:
A61K 48/00
A61K 47/48
Abstract:
The present invention is directed to reversibly inactivated membrane active polymers useful for cellular delivery of compounds. Described are polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
Control profile
Kirk E Ekena from Raleigh, NC, age ~57 Get Report